Sinovac Life Sciences Co., Ltd. (Sinovac), a subsidiary of Sinovac, has secured $500 million in funding for further development, capacity expansion, and manufacturing of their COVID-19 vaccine known as CoronaVac. The investor is called Sino Biopharmaceutical Limited,...
Sinovac
Category
Phase 1 & 2 Study Reveals CoronaVac COVID-19 Vaccine Candidate Inferior to BNT162B2 & mRNA-1273
A Chinese firm, known as Sinovac, one of the leading COVID-19 vaccine developer contenders, recently revealed results from a peer-reviewed paper in the medical journal The Lancet. Collected from its first Phase 1 and Phase 2 clinical trials investigating the...
Sinovac’s CoronaVac trial reauthorized by Anvisa: Phase 3 Clinical Trial Continues on
TrialSite recently reported that the Brazilian drug regulatory authority has halted the Sinovac (CoronaVac) COVID-19 vaccine trial, however days later Brazil’s National Health Surveillance Agency (Anvisa) authorized the resumption of the Phase 3 clinical trial testing...
Brazil’s Drug Regulator ANVISA Halts Sinovac Phase 3 Vaccine Although Principal Investigator Declares Death Not Related to Study
ANVISA, Brazil’s drug regulatory, halted the Sinovac Phase 3 clinical trial testing the Chinese company’s COVID-19 vaccine after a volunteer participating in the clinical trial apparently died on Oct. 29. However, according to the principal investigator leading the...
Sinovac Clinical Trials Halted in Brazil Due to Severe Adverse Event
In early September, the AstraZeneca/Oxford vaccine trials were put on temporary hold across all international testing sites due to a volunteer developing an unexplained illness and died. Similarly, Anvisa, Brazil's National Health Surveillance Agency, just recently...
Indonesia Secures Deal with AstraZeneca for 100 Million Doses of AZD1222 to Fight COVID-19
The nation of Indonesia, the fourth most populous worldwide, has inked a deal with AstraZeneca to buy 100 million COVID-19 vaccines next year. Known as AZD1222 (Oxford vaccine), Indonesia Foreign Minister Retno Marsudi signed a letter of intent while visiting with...
Sinovac Cash Problems? Bangladesh Phase 3 Clinical Trial at Risk
Bangladesh’s health ministry has rejected calls by China’s Sinovac Biotech to co-finance a Phase 3 COVID-19 vaccine-focused clinical trial in that country. Last month, Sinovac Biotech Ltd sent a letter to the health ministry declaring that unless funds were...
Will China Supply Much of the World’s Vaccine for COVID-19? WHO In Discussions to do Just That
The World Health Organization (WHO) now purportedly considers China as its strategic COVID-19 vaccine supplier as the world’s most populous nation—representing the second largest GDP rapidly gaining on the United States—makes its moves to become the world’s primary...
COVID-19 Vaccine Clinical Trials & Manufacturing Hub in Egypt: All Chinese with Sinopharm & Sinovac
Egypt reports via its Minister of Higher Education and Scientific Research that that influential Arabic nation will conduct two Phase COVID-19 vaccine clinical trials in partnership with China’s Sinopharm Group. Egypt is an important market for the vaccine producers....
Phase 3 CoronaVac Trial in Indonesia Moves Along while BPOM Plans an Audit of Sinovac Facility in China
Thus far, Indonesian authorities report the relatively smooth running of the Phase 3 Sinovac COVID-19 clinical trial vaccine candidate. Conducted in Bandung, West Java, the local press reports no participants with “grave symptoms” after the injections. Retno Marsudi,...
Better Safe Than Sorry: East Focuses on Expediency While West Focuses on Safety of COVID-19 Vaccines
On August 31, TrialSite reported that Chinese regulators were expediting acceptance of drug makers’ investigational products with emergency use authorizations for Sinovac Biotech’s (Sinovac) CoronaVac, Sinopharm, as well as CanSino Biologics’ Ad5-nCoV, the latter of...
Leading Korean CRO Selected to Run Sinovac Phase 3 COVID-19 Vaccine Trial in Bangladesh
A leading Korean contract research organization (CRO) called LSK Global Pharma Services will conduct the Phase 3 clinical trial of Sinovac’s COVID-19 vaccine candidate in Bangladesh. Targeting approximately 4,200 frontline health workers at seven Dhaka-based...
Indonesia Testing Location for China’s Sinovac Phase 3 Clinical Trial
Sinovac, one of the leading COVID-19 vaccine developers, initiated Phase 3 clinical trial in Indonesia where about 800 participants have registered for the clinical trial. Led by Padjajaran University (Unpad), Medical School’s Kusnandi Rusmil reports the clinical...
Indonesia Joins Sinovac to Initiate Phase 3 Testing of CoronaVac While Securing Option to Purchase 100m Doses
Indonesia’s Bio Farma, a state-run pharmaceutical company, plans to produce 100 million doses of COVID-19 vaccine product developed by Sinovac. In a deal that is contingent on a successful Phase 3 clinical trial in the world’s third most populous nation, Sinovac has...
CoronaVac Moves to Phase 3 Clinical Trial in Brazil with Up to 9,000 to be Enrolled
Sinovac Biotech Ltd. (“Sinovac”) (Nasdaq: SVA), a Chinese biopharmaceutical company developing a COVID-19 vaccine candidate (CoronaVac), announced that its Brazilian partner Instituto Butantan, a producer of immunobiological products and vaccines, received...
Sinovac Reports Positive Phase I/II Results for COVID-19 Vaccine & Moving to Phase III—Is there an Investor Elephant in the Room?
Sinovac Biotech Ltd. (Nasdaq: SVA) reports positive preliminary results of its Phase I/II clinical trial for CoronaVac, the company’s COVID-19 vaccine candidate. Recent results, according to the company, evidence favorable immunogenicity and safety profiles. The...
Philippines Active in COVID-19 Clinical Trials & Invites Sinovac Biotech for Vaccine Trial
The Philippines government has arranged to investigate a diversified basket of investigational assets targeting COVID-19. Now government health executives are on the move, preparing for new COVID-19 vaccine & antiviral trials while 20 hospitals participate in...
Sinovac Secures $15m Via Convertible Debt Deal to Support Race to Produce COVID-19 Vaccine ‘CoronaVac’
Sinovac Biotech Ltd (Sinovac) (NASDAQ: SVA) is a Chinese biotech company vying for a leading position in the race to develop a COVID-19 vaccine. Recently, its wholly-owned subsidiary, Sinovac Research and Development Co., Ltd, (Sinovac R&D) received a $15 million...
Sinovac’s PiCoVacc Experimental Vaccine Shows Promise in Monkeys Infected with SARS-CoV-2
A preclinical animal study in China has produced a study result that an early stage vaccine called PiCoVacc can block SARS-CoV-2. Researchers working for Sinovac Biotech Ltd. reported in a recent preprint server (not peer reviewed) study that the team administered...
China’s Sinovac Biotech inks Partnership with Dynavax for its Vaccine Adjuvant CpG 1018
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Sinovac Biotech Ltd (SVA), a leading provider of biopharmaceutical products in China, announced a new partnership into a collaboration to...